Document:

exv10w1

EXHIBIT 10.1

FORM
OF WARRANT EXCHANGE AGREEMENT

          THIS WARRANT EXCHANGE AGREEMENT (the “Agreement”) is dated as of January 18, 2011, by and
between OXiGENE, Inc., a Delaware corporation with offices located at 701 Gateway Blvd, Suite 210,
South San Francisco, CA 94080 (the “Company”), and _______________ (the “Investor”).

          WHEREAS:

          A. The Company, the Investor and certain other investors (the “Other Investors” and together
with the Investor, the “Investors”) are parties to that certain Securities Purchase Agreement,
dated as of March 10, 2010, as amended by that certain Amendment and Exchange Agreement dated as of
March 25, 2010 (the “Existing Securities Purchase Agreement”), pursuant to which, among other
things, the Investor purchased from the Company (i) certain shares of the Company’s common stock,
par value $0.01 per share (the “Common Stock”), (ii) a Series A Warrant, which is currently
exercisable into _______ shares of Common Stock (the “Series A Warrant”), (iii) a Series B Warrant,
which was exercisable into shares of Common Stock and which has expired prior to the date of this
Agreement, (iv) a Series C Warrant, which is currently exercisable into _______ shares of Common
Stock (the “Series C Warrant”), and (v) a Series D Warrant, which was exercisable into shares of
Common Stock and which has expired prior to the date of this Agreement.

          B. The Company and the Investor desire to enter into this Agreement, pursuant to which, among
other things, the Company and the Investor shall (x) at the Initial Closing (as defined below),
exchange the Series A Warrant and the Series C Warrant currently held by the Investor for (i)
______ shares of Common Stock (the “Initial Closing Shares”), and (ii) a warrant in the form
attached hereto as Exhibit A (the “Series E Warrant”), initially exercisable into ________
shares of Common Stock (the “Series E Warrant Shares”) and (y) subject to occurrence of the
Stockholder Approval (as defined below), at the Second Closing (as defined below), exchange the
Series E Warrant then held by the Investor for ________ shares of Common Stock (the “Second Closing
Shares”), each as described below.

          C. As a closing condition to the transactions contemplated hereby, each of the Other Investors
are executing agreements identical to this Agreement (other than proportional changes in the
numbers reflecting (x) such different number of shares of Common Stock (the “Other Initial Closing
Shares”) and such warrants (the “Other Series E Warrants”, and together with the Series E Warrant,
the “Series E Warrants”) exercisable into such different number of shares of Common Stock (the
“Other Series E Warrant Shares”) to be issued to each such Other Investor in exchange for the
Series A Warrant (as defined in the Existing Securities Purchase Agreement) and Series C Warrant
(as defined in the Existing Securities Purchase Agreement) of such Other Investor concurrently with
the Initial Closing and (y) such different number of shares of Common Stock (the “Other Second
Closing Shares”, and together with the Initial Closing Shares, the Other Initial Closing Shares and
the Second Closing Shares, collectively, the “Exchange Shares”) to be issued to each such Other
Investor in

 

 

exchange for the Series E Warrant of such Other Investor concurrently with the Second Closing,
in each case, pursuant to separate agreements dated of even date herewith) (the “Other Agreements,”
and together with this Agreement, the “Agreements”).

          D. The exchange of (x) the Series A Warrant and the Series C Warrant for the Initial Exchange
Shares and the Series E Warrant at the Initial Closing and (y) the Series E Warrant for the Second
Closing Shares at the Second Closing are each being made in reliance upon the exemption from
registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the “1933
Act”); and

          E. The Initial Closing Shares, the Other Initial Closing Shares, the Second Closing Shares,
the Other Second Closing Shares, the Series E Warrants, the Other Series E Warrants, the Series E
Warrant Shares and the Other Series E Warrant Shares are collectively referred to herein as the
“Securities”.

          F. Capitalized terms used but not otherwise defined herein shall have the meanings as set
forth in the Existing Securities Purchase Agreement as amended hereby.

          NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants
hereinafter contained, the parties hereto agree as follows:

     1. EXCHANGES.

          1.1 Initial Exchange. Subject to the satisfaction or waiver of the conditions with
respect to the Initial Closing set forth in Sections 5 and 6 below, at the Initial Closing the
Investor and the Company shall, pursuant to Section 3(a)(9) of the 1933 Act, exchange the Series A
Warrant and the Series C Warrant for the Initial Exchange Shares and the Series E Warrant, as
follows (the “Initial Exchange”):

          (a) Initial Closing. The issuance of the Initial Closing Shares and the Series
E Warrant (the “Initial Closing”) shall occur at the offices of Greenberg Traurig, LLP,
MetLife Building, 200 Park Avenue, New York, NY 10166. The date and time of the Initial
Closing shall be 10:00 a.m., New York time, on the first (1st) Business Day on
which the conditions to the Initial Closing set forth in Sections 5 and 6 below are
satisfied or waived (or such later date as is mutually agreed to by the Company and each
Investor).

          (b) Consideration. At the Initial Closing, the Initial Closing Shares and the
Series E Warrant shall be issued to the Investor in exchange for the Series A Warrant and
the Series C Warrant without the payment of any additional consideration.

          (c) Delivery. In exchange for the Series A Warrant and the Series C Warrant,
the Company shall, at the Initial Closing, (i) deliver or cause to be delivered to the
Investor certificates for the Series E Warrant and (ii) cause American Stock Transfer &
Trust Company, LLC (together with any subsequent transfer agent, the “Transfer Agent”)
through the Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program, to
credit the Initial Closing Shares to the Investor’s or its designee’s balance account with
DTC through its Deposit/Withdrawal at Custodian system. The Investor shall deliver or cause
to be delivered to the Company (or its designee) the

2

 

original Series A Warrant and the original Series C Warrant, as soon as commercially
practicable following the Initial Closing. As of the Initial Closing Date, all of the
Investor’s rights under the Series A Warrant and the Series C Warrant shall be extinguished.

          1.2 Second Exchange. Subject to the satisfaction or waiver of the conditions with
respect to the Second Closing set forth in Sections 5 and 6 below and the Company obtaining the
Stockholder Approval (as defined below), at the Second Closing the Investor and the Company shall,
pursuant to Section 3(a)(9) of the 1933 Act, exchange the Series E Warrant for the Second Closing
Shares, as follows (the “Second Exchange”, and together with the Initial Exchange, the
“Exchanges”):

          (a) Special Meeting. The Company shall use its reasonable best efforts to
provide each of its stockholders entitled to vote at a special meeting of stockholders of
the Company (the “Stockholder Meeting”), which shall be promptly called and held not later
than February 28, 2011 (or in the event that such proxy statement is subject to a full
review by the SEC, March 31, 2011), a proxy statement, substantially in a form which shall
have been previously reviewed by Greenberg Traurig LLP, at the expense of the Company but in
any event such expense not to exceed $10,000 without the prior written approval of the
Company; soliciting each such stockholder’s affirmative vote at the Stockholder Meeting for
the approval of resolutions (“Stockholder Resolutions”) providing for the Company’s issuance
of all of the Securities as described in the Agreements in accordance with applicable law
and the rules and regulations of the Principal Market (such affirmative approval being
referred to herein as the “Stockholder Approval”, and the date such Stockholder Approval is
obtained, the “Stockholder Approval Date”), and the Company shall use its reasonable best
efforts to solicit its stockholders’ approval of such resolutions and to cause the Board of
Directors of the Company to recommend to the stockholders that they approve such
resolutions. The Company shall be obligated to seek to obtain the Stockholder Approval by
the Stockholder Meeting deadline set forth above. If, despite the Company’s reasonable best
efforts the Stockholder Approval is not obtained on or prior to such Stockholder Meeting
deadline and the Company’s stockholders authorize an adjournment of the Stockholder Meeting
to solicit additional proxies, then, for the sake of economy, the Company shall so adjourn
the Stockholder Meeting and continue using its reasonable best efforts to solicit sufficient
additional proxies to obtain the Stockholder Approval through and until the sooner of such
time as the Company obtains the Stockholder Approval or May 18, 2011. If, however, the
Company’s stockholders do not approve the adjournment of the Stockholder Meeting, the
Company shall cause an additional Stockholder Meeting to be held once in each subsequent
calendar quarter thereafter, provided however that the Company shall have no obligation to
seek Stockholder Approval after May 18, 2011.

          (b) Second Closing. The issuance of the Second Closing Shares (the “Second
Closing”) shall occur at the offices of Greenberg Traurig, LLP, MetLife Building, 200 Park
Avenue, New York, NY 10166. The date and time of the Second Closing shall be 10:00 a.m., New
York time, on the first (1st) Business Day on which the conditions to the Second
Closing set forth in Sections 5 and 6 below are satisfied or waived (or such later date as
is mutually agreed to by the Company and each Investor).

3

 

          (c) Consideration. At the Second Closing the Second Closing Shares shall be
issued to the Investor in exchange for the Series E Warrant without the payment of any
additional consideration.

          (d) Delivery. In exchange for the Series E Warrant, the Company shall, at the
Second Closing, cause the Transfer Agent through the DTC Fast Automated Securities Transfer
Program, to credit the Second Closing Shares to the Investor’s or its designee’s balance
account with DTC through its Deposit/Withdrawal at Custodian system. The Investor shall
deliver or cause to be delivered to the Company (or its designee) the original Series E
Warrant as soon as commercially practicable following the Initial Closing. As of the Second
Closing Date, all of the Investor’s rights under the Series E Warrant shall be extinguished.

          1.3 Other Documents. The Company and the Investor shall execute and/or deliver such
other documents and agreements as are reasonably necessary to effectuate the Exchanges.

     2. AMENDMENTS TO TRANSACTION DOCUMENTS.

          2.1 Ratifications. Except as otherwise expressly provided herein, the Existing
Securities Purchase Agreement and each other Transaction Document, is, and shall continue to be, in
full force and effect and is hereby ratified and confirmed in all respects, except that on and
after the Closing Date: (i) all references in the Existing Securities Purchase Agreement to “this
Agreement”, “hereto”, “hereof”, “hereunder” or words of like import referring to the Existing
Securities Purchase Agreement shall mean the Existing Securities Purchase Agreement as amended by
this Agreement, and (ii) all references in the other Transaction Documents, to the “Securities
Purchase Agreement”, “thereto”, “thereof”, “thereunder” or words of like import referring to the
Securities Purchase Agreement shall mean the Existing Securities Purchase Agreement as amended by
this Agreement.

          2.2 Amendments to Transaction Documents. On and after the Closing Date, each of the
Transaction Documents and Schedule 3.2 hereof are hereby amended as follows:

          (a) The defined term “Common Shares” is hereby amended to include “the Exchange Shares” (as
defined in the Warrant Exchange Agreements)”.

          (b) The defined term “Series A Warrants” is hereby amended to include “the Series E Warrants
(as defined in the Warrant Exchange Agreements)”.

          (c) The defined term “Series A Warrant Shares” is hereby amended to include “the Series E
Warrant Shares (as defined in the Warrant Exchange Agreements) and the Other Series E Warrant
Shares (as defined in the Warrant Exchange Agreements)”.

          (d) The defined term “Warrant Exchange Agreements” shall mean “those certain Warrant Exchange
Agreements, dated as of January 18, 2011, each by and between the Company and each Buyer”.

4

 

          (e) The defined term “Transaction Documents” is hereby amended to include the Warrant Exchange
Agreements.

          2.3 Amendment to Existing Securities Purchase Agreement. On and after the Closing
Date, the Existing Securities Purchase Agreement is hereby amended as follows:

          (a) Section 4(o)(i) is hereby amended such that:

               (i) the reference to “five (5) Trading Days” is hereby replaced by “three (3)
Trading Days”;

               (ii) the reference to “three (3) Trading Days” is hereby replaced by “two (2)
Trading Days”; and

               (iii) the reference to “two (2) Trading Days” is hereby replaced by “one (1)
Trading Day”.

          (b) Section 4(o)(ii) is hereby amended such that:

               (i) the reference to the “third (3 rd) Business Day” is hereby replaced by the
“second (2 nd) Business Day”; and

               (ii) the reference to the “fifth (5 th) Business Day” is hereby replaced by the
“second (2 nd) Business Day”.

     3. REPRESENTATIONS AND WARRANTIES

          3.1 Investor Bring Down. The Investor hereby represents and warrants to the Company
with respect to itself only as set forth in Section 2 of the Existing Securities Purchase Agreement
(as amended hereby) as to this Agreement as if such representations and warranties were made as of
the date hereof and set forth in their entirety in this Agreement. Such representations and
warranties to the transactions thereunder and the securities issued pursuant thereto are hereby
deemed for purposes of this Agreement to be references to the transactions hereunder and the
issuance of the securities pursuant hereto.

          3.2 Company Bring Down. Except as set forth on Schedule 3.2 attached hereto,
the Company represents and warrants to the Investor as set forth in Section 3 of the Existing
Securities Purchase Agreement (as amended hereby) as if such representations and warranties were
made as of the date hereof and set forth in their entirety in this Agreement (other than Sections
3(a), 3(c), 3(e), 3(n) and 3(r) of the Existing Securities Purchase Agreement, which shall be
deemed to be amended and restated in the form attached hereto on Schedule 3.2 (as amended
by Section 2.2 hereof)). Such representations and warranties to the transactions thereunder and
the securities issued pursuant thereto are hereby deemed for purposes of this Agreement to be
references to the transactions hereunder and the issuance of the securities pursuant hereto,
references therein to “Closing Date” being deemed references to the Initial Closing Date or the
Second Closing Date, as applicable, and references to “the date hereof” being deemed references to
the date of this Agreement.

5

 

     4. COVENANTS.

          4.1 Reasonable Best Efforts. The Company shall use its reasonable best efforts to
timely satisfy each of the conditions to be satisfied by it as provided in Section 6 of this
Agreement. The Investor shall use its reasonable best efforts to timely satisfy each of the
conditions to be satisfied by it as provided in Section 5 of this Agreement.

          4.2 Disclosure of Transactions and Other Material Information. On or before 9:30 a.m.,
New York time, on the first (1st) Business Day following the date of this Agreement, the Company
shall file a Current Report on Form 8-K describing all the material terms of the transactions
contemplated by the Agreement in the form required by the Securities Exchange Act of 1934, as
amended, and attaching this Agreement and the form of the Series E Warrant thereto as exhibits
(including all attachments, the “8-K Filing”). From and after the issuance of the 8-K Filing, the
Company shall have disclosed all material, non-public information (if any) delivered to any of the
Investors by the Company or any of its Subsidiaries, or any of their respective officers,
directors, employees or agents in connection with the transactions contemplated by this Agreement.
On or before 9:30 a.m., New York time, on the Initial Closing Date, the Company shall file a
Current Report on Form 8-K certifying that the Initial Exchange has been consummated. On or before
9:30 a.m., New York time, on the Second Closing Date, the Company shall file a Current Report on
Form 8-K certifying that the Second Exchange has been consummated.

          4.3 Fees. The Company shall reimburse Greenberg Traurig, LLP (counsel to the lead
Investor), on demand, for all reasonable, documented costs and expenses incurred by it in
connection with preparing and delivering this Agreement (including, without limitation, all
reasonable, documented legal fees and disbursements in connection therewith, and due diligence in
connection with the transactions contemplated thereby), provided, however, that the amount payable
by the Company to Greenberg Traurig, LLP in connection with this Agreement shall not exceed $15,000
in the aggregate unless previously agreed to in writing by the Company.

          4.4 Holding Period. For the purposes of Rule 144, the Company acknowledges that the
holding period of (x) the Initial Closing Shares, the Series E Warrants and the Series E Warrant
Shares (if acquired using a Cashless Exercise (as defined in the Series E Warrant)) may be tacked
onto the holding period of the Series A Warrants and the Series C Warrants and (y) the Second
Closing Shares may be tacked onto the holding period of the Series E Warrants, and the Company
agrees not to take a position contrary to this Section 4.4.

          4.5 No Ability to Vote Shares Issued at First Closing. As required by the rules and
regulations of the Principal Market, the Investor covenants and agrees not vote its Initial Closing
Shares at the Special Meeting.

          4.6 No Waiver of Voting Agreements. The Company shall not amend, waive or modify any
provision of the Voting Agreements (as defined below).

     5. CONDITIONS TO COMPANY’S OBLIGATIONS HEREUNDER.

     The obligations of the Company to the Investor hereunder are subject to the satisfaction of
each of the following conditions (except to the extent such condition is expressly conditional

6

 

to a specific closing, in which case such condition shall only apply to such specific
closing), provided that these conditions are for the Company’s sole benefit and may be waived by
the Company at any time in its sole discretion by providing the Investor with prior written notice
thereof:

          5.1 The Investor shall have duly executed this Agreement and delivered the same to the
Company.

          5.2 Each of the Other Investors shall have duly executed the Other Agreement of such Other
Investor and delivered the same to the Company.

          5.3 The representations and warranties of the Investor shall be true and correct in all
material respects as of the date when made and as of each Closing Date as though made at that time
(except for representations and warranties that speak as of a specific date which shall be true and
correct as of such specified date), and the Investor shall have performed, satisfied and complied
in all material respects with the covenants, agreements and conditions required by this Agreement
to be performed, satisfied or complied with by the Investor at or prior to each Closing Date.

          5.4 With respect to the Second Closing only, the Stockholder Approval shall have occurred.

     6. CONDITIONS TO INVESTOR’S OBLIGATIONS HEREUNDER.

     The obligations of the Investor hereunder are subject to the satisfaction of each of the
following conditions (except to the extent such condition is expressly conditional to a specific
closing, in which case such condition shall only apply to such specific closing), provided that
these conditions are for the Investor’s sole benefit and may be waived by the Investor at any time
in its sole discretion by providing the Company with prior written notice thereof:

          6.1 The Company shall have duly executed and delivered this Agreement to the Investor.

          6.2 At the Initial Closing, the Company shall have duly executed and delivered (or caused to
be delivered) to the Investor the certificate with respect to the Series E Warrant and
electronically delivered to the Investor (or its designee) through DTC the Initial Closing Shares.
At the Second Closing, the Company shall have electronically delivered to the Investor (or its
designee) through DTC the Second Closing Shares.

          6.3 The Company shall have delivered to the Investor a copy of each Other Agreement, duly
executed and delivered by the Company and each Other Investor party thereto.

          6.4 The Investor shall have received the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and
Popeo, P.C., the Company’s counsel, dated as of the applicable Closing Date, in the form reasonably
acceptable to the Investor.

          6.5 The Company shall have delivered to the Investor a copy of the Amended and Restated
Irrevocable Transfer Agent Instructions, in the form acceptable to the Investor,

7

 

which instructions shall have been delivered to and acknowledged in writing by the Company’s
transfer agent.

          6.6 The Company shall have delivered to the Investor a certificate, in the form acceptable to
the Investor, duly executed by the Secretary of the Company and dated as of each Closing Date, as
to (i) the resolutions authorizing the transactions contemplated hereby as adopted by the Company’s
board of directors, in a form reasonably acceptable to the Investor, (ii) the Certificate of
Incorporation of the Company and (iii) the Bylaws of the Company, each as in effect at each
Closing.

          6.7 Each and every representation and warranty of the Company shall be true and correct in all
material respects as of the date when made and as of each Closing Date as though originally made at
that time (except for representations and warranties that speak as of a specific date, which shall
be true and correct as of such date) and the Company shall have performed, satisfied and complied
in all material respects with the covenants, agreements and conditions required to be performed,
satisfied or complied with by the Company at or prior to each Closing Date. The Investor shall have
received a certificate, duly executed by the Chief Executive Officer of the Company, dated as of
each Closing Date, to the foregoing effect and as to such other matters as may be reasonably
requested by the Investor in the form acceptable to the Investor.

          6.8 The Company shall have obtained all governmental, regulatory or third party consents and
approvals, if any, necessary for the transactions contemplated by this Agreement, including without
limitation, those required by the Principal Market, except for the Stockholder Approval.

          6.9 No statute, rule, regulation, executive order, decree, ruling or injunction shall have
been enacted, entered, promulgated or endorsed by any court or governmental authority of competent
jurisdiction that prohibits the consummation of any of the transactions contemplated by this
Agreement.

          6.10 The Company and its Subsidiaries shall have delivered to the Investor such other
documents relating to the transactions contemplated by this Agreement as the Investor or its
counsel may reasonably request.

          6.11 The Company shall have duly executed and delivered to such Investor voting agreements in
the form of Exhibit B hereto (the “Voting Agreements”), by and between the Company and each
of its executive officers, directors and Symphony Capital LLC (the “Principal Stockholders”) and
the Principal Stockholders shall have duly executed and delivered to such Investor the Voting
Agreements.

          6.12 With respect to the Second Closing only, the Stockholder Approval shall have occurred
prior to May 18, 2011.

     7. TERMINATION.

     In the event that the First Closing does not occur on or before five (5) Business Days from
the date hereof due to the Company’s or the Investor’s failure to satisfy the conditions

8

 

set forth in Sections 5 and 6 hereof (and the nonbreaching party’s failure to waive such
unsatisfied conditions(s)), the nonbreaching party shall have the option to terminate this
Agreement with respect to such breaching party at the close of business on such date without
liability of any party to any other party. Upon such termination, the terms hereof shall be null
and void and the parties shall continue to comply with all terms and conditions of the Transaction
Documents, as in effect prior to the execution of this Agreement; provided further that no such
termination shall affect any obligation of the Company under this Agreement to reimburse Greenberg
Traurig LLP for the expenses described in Section 4.3 above.

     8. MISCELLANEOUS.

          8.1 Miscellaneous Provisions. Section 9 of the Existing Securities Purchase Agreement
is hereby incorporated by reference herein, mutatis mutandis.

          8.2 Legends. No restrictive legends shall be placed on the certificates representing
the Securities.

          8.3 Most Favored Nation. The Company hereby represents and warrants as of the date
hereof and covenants and agrees from and after the date hereof that none of the terms offered to
any Person with respect to any consent, release, amendment, settlement or waiver relating to the
terms, conditions and transactions contemplated hereby (each a “Settlement Document”), is
or will be more favorable to such Person than those of the Investor and this Agreement. If, and
whenever on or after the date hereof, the Company enters into a Settlement Document, then (i) the
Company shall provide notice thereof to the Investor immediately following the occurrence thereof
and (ii) the terms and conditions of this Agreement, the other Exchange Documents and the
Securities (other than any limitations on conversion or exercise set forth therein) shall be,
without any further action by the Investor or the Company, automatically amended and modified in an
economically and legally equivalent manner such that the Investor shall receive the benefit of the
more favorable terms and/or conditions (as the case may be) set forth in such Settlement Document,
provided that upon written notice to the Company at any time the Investor may elect not to accept
the benefit of any such amended or modified term or condition, in which event the term or condition
contained in this Agreement or the Securities (as the case may be) shall apply to the Investor as
it was in effect immediately prior to such amendment or modification as if such amendment or
modification never occurred with respect to the Investor. The provisions of this Section 8.3 shall
apply similarly and equally to each Settlement Document.

          8.4 No Commissions. Neither the Company nor the Investor has paid or given, or will
pay or give, to any person, any commission or other remuneration, directly or indirectly, in
connection with the transactions contemplated by this Agreement.

          8.5 No Registration or Listing. Notwithstanding anything set forth herein or in the
Transaction Documents as amended hereby, the Investor hereby acknowledges and agrees that the
Company shall have no obligation to register the Series E Warrant Shares with the Securities and
Exchange Commission, nor shall the Company have any obligation to cause the Series E Warrants to be
listed on the OTC Bulletin Board.

9

 

[The remainder of the page is intentionally left blank]

10

 

          IN WITNESS WHEREOF, the Investor and the Company have caused their respective signature pages
to this Agreement to be duly executed as of the date first written above.

	 	 	 	 	 
	 	COMPANY:

OXIGENE, INC.

 	 
	 	By:  	 	 
	 	 	Name:  	Dr. Peter J. Langecker 	 
	 	 	Title:  	Chief Executive Officer 	 

 

 

	 	 	 	 	 

     IN WITNESS WHEREOF, the Investor and the Company have caused their respective signature pages
to this Agreement to be duly executed as of the date first written above.

	 	 	 	 	 
	 	INVESTOR:

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 	o Notwithstanding anything contained in this Agreement to the
contrary, by checking this box (i) the obligations of the above-signed to
exchange the securities set forth in this Agreement to be exchanged from the
Company by the above-signed, and the obligations of the Company to sell such
securities to the above-signed, shall be unconditional and all conditions to
Closing shall be disregarded, (ii) the Closing shall occur no later than the
third (3rd) Trading Day following the date of this Agreement and
(iii) any condition to Closing contemplated by this Agreement (but prior to
being disregarded by clause (i) above) that required delivery by the Company or
the above-signed of any agreement, instrument, certificate or the like or
purchase price (as applicable) shall no longer be a condition and shall instead
be an unconditional obligation of the Company or the above-signed (as
applicable) to deliver such agreement, instrument, certificate or the like or
exchange securities (as applicable) to such other party on the Closing Date.

 

 

Schedule 2.2: 

     3(a): Organization and Qualification. Each of the Company and each of its Subsidiaries are
entities duly organized and validly existing and in good standing under the laws of the
jurisdiction in which they are formed, and have the requisite power and authorization to own their
properties and to carry on their business as now being conducted and as presently proposed to be
conducted. With the exception of the Company’s “forfeited” status in the State of California, each
of the Company and each of its Subsidiaries is duly qualified as a foreign entity to do business
and is in good standing in every jurisdiction in which its ownership of property or the nature of
the business conducted by it makes such qualification necessary, except to the extent that the
failure to be so qualified or be in good standing would not have a Material Adverse Effect. As used
in this Agreement, “Material Adverse Effect” means any material adverse effect on (i) the business,
properties, assets, liabilities, operations (including results thereof), condition (financial or
otherwise) or prospects of the Company or any Subsidiary, individually or taken as a whole, (ii)
the transactions contemplated hereby or in any of the other Transaction Documents or (iii) the
authority or ability of the Company or any of its Subsidiaries to perform any of their respective
obligations under any of the Transaction Documents (as defined below). The Company has no
Subsidiaries. “Subsidiaries” means any Person in which the Company, directly or indirectly, (I)
owns at least fifty percent (50% of the outstanding capital stock or holds at least fifty percent
(50%) of the equity or similar interest of such Person or (II) controls or operates all or any part
of the business, operations or administration of such Person, and each of the foregoing, is
individually referred to herein as a “Subsidiary.”

     3(c): Issuance of Securities. The Common Shares, when issued, will be validly issued, fully paid and nonassessable and free
from all preemptive or similar rights, taxes, liens, charges and other encumbrances with respect to
the issue thereof, with the holders being entitled to all rights accorded to a holder of Common
Stock. The Warrants are duly authorized and upon issuance in accordance with the terms of the
Transaction Documents shall be validly issued, fully paid and non-assessable and free from all
preemptive or similar rights, taxes, liens, charges and other encumbrances with respect to the
issue thereof. As of the Closing, the Company shall have reserved from its duly authorized capital
stock not less than 100% of the maximum number of Warrant Shares issuable upon exercise of the
Warrants as of such date (without taking into account any possible adjustments pursuant to the
anti-dilution rights attendant thereto or any limitations on the exercise of the Warrants set forth
therein). Upon exercise in accordance with the Warrants, the Warrant Shares, when issued, will be
validly issued, fully paid and nonassessable and free from all preemptive or similar rights, taxes,
liens, charges and other encumbrances with respect to the issue thereof, with the holders being
entitled to all rights accorded to a holder of Common Stock. Subject to the accuracy of the
representations and warranties of the Buyers in this Agreement, the offer and issuance by the
Company of the Securities is exempt from registration under the 1933 Act.

     3(e): Consents. Other than the Stockholder Approval (as defined in the Warrant Exchange Agreements),
neither the Company nor any Subsidiary is required to obtain any consent from,
authorization or order of, or make any filing or registration with (other than the filing with
the SEC of one or more Registration Statements in accordance with the requirements of the
Registration Rights Agreement, a Form D with the SEC and any other filings as may be required by
any state securities agencies), any court, governmental agency or any regulatory or

 

 

self-regulatory
agency or any other Person in order for it to execute, deliver or perform any of its respective
obligations under or contemplated by the Transaction Documents, in each case, in accordance with
the terms hereof or thereof. Other than the Stockholder Approval, all consents, authorizations,
orders, filings and registrations which the Company or any Subsidiary is required to obtain
pursuant to the preceding sentence have been obtained or effected on or prior to the Closing Date,
and neither the Company nor any of its Subsidiaries are aware of any facts or circumstances which
might prevent the Company or any Subsidiary from obtaining or effecting any of the registration,
application or filings contemplated by the Transaction Documents. Except as set forth in the SEC
Documents, the Company is not in violation of the requirements of the Principal Market and has no
knowledge of any facts or circumstances which could reasonably lead to delisting or suspension of
the Common Stock in the foreseeable future.

     3(n): Conduct of Business; Regulatory Permits. Neither the Company nor any of its Subsidiaries is in violation of any term of or in default
under its Certificate of Incorporation, Bylaws, any certificate of designation, preferences or
rights of any other outstanding series of preferred stock of the Company or any of its Subsidiaries
or their organizational charter, certificate of formation or certificate of incorporation or
bylaws, respectively. Neither the Company nor any of its Subsidiaries is in violation of any
judgment, decree or order or any statute, ordinance, rule or regulation applicable to the Company
or any of its Subsidiaries, and neither the Company nor any of its Subsidiaries will conduct its
business in violation of any of the foregoing, except in all cases for possible violations which
could not, individually or in the aggregate, have a Material Adverse Effect. Without limiting the
generality of the foregoing, other than as set forth in the SEC Documents, the Company is not in
violation of any of the rules, regulations or requirements of the Principal Market and has no
knowledge of any facts or circumstances that could reasonably lead to delisting or suspension of
the Common Stock by the Principal Market in the foreseeable future. Since January 1, 2008, other
than as set forth in the SEC Documents, (i) the Common Stock has been listed or designated for
quotation on the Principal Market, (ii) trading in the Common Stock has not been suspended by the
SEC or the Principal Market and (iii) the Company has received no communication, written or oral,
from the SEC or the Principal Market regarding the suspension or delisting of the Common Stock from
the Principal Market. The Company and each of its Subsidiaries possess all certificates,
authorizations and permits issued by the appropriate regulatory authorities necessary to conduct
their respective businesses, except where the failure to possess such certificates, authorizations
or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither
the Company nor any such Subsidiary has received any notice of proceedings relating to the
revocation or modification of any such certificate, authorization or permit.

     3(r): Equity Capitalization. As of the date hereof, the authorized capital stock of the Company consists of (i)
300,000,000 shares of Common Stock, of which, subject to Schedule 3(r), 110,244,595 are
issued and outstanding and 64,861,822 shares are reserved for issuance pursuant to securities
(other than the Warrants) exercisable or exchangeable for, or convertible into, shares of Common
Stock and (ii) 15,000,000 shares of Preferred Stock, $0.01 par value, of which none are
outstanding. No shares of Common Stock are held in treasury. All of such outstanding shares are
duly authorized and have been, or upon issuance will be, validly issued and are fully paid and
nonassessable. 28,294,274 shares of the Company’s issued and outstanding Common Stock on the date
hereof are as of the date hereof owned by Persons who are “affiliates” (as defined in Rule 405 of
the 1933 Act and calculated based on the assumption

 

 

that only officers, directors and holders of at
least 10% of the Company’s issued and outstanding Common Stock are “affiliates” without conceding
that any such Persons are “affiliates” for purposes of federal securities laws) of the Company or
any of its Subsidiaries. To the Company’s knowledge, as of the date hereof, except as set forth in
the SEC Documents, no Person owns 10% or more of the Company’s issued and outstanding shares of
Common Stock (calculated based on the assumption that all Equivalents, whether or not presently
exercisable or convertible, have been fully exercised or converted (as the case may be) taking
account of any limitations on exercise or conversion (including “blockers”) contained therein
without conceding that such identified Person is a 10% stockholder for purposes of federal
securities laws). Except as disclosed in the SEC Documents: (i) none of the Company’s or any
Subsidiary’s capital stock is subject to preemptive rights or any other similar rights or any liens
or encumbrances suffered or permitted by the Company or any Subsidiary; (ii) there are no
outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable
for, any capital stock of the Company or any of its Subsidiaries, or contracts, commitments,
understandings or arrangements by which the Company or any of its Subsidiaries is or may become
bound to issue additional capital stock of the Company or any of its Subsidiaries or options,
warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating
to, or securities or rights convertible into, or exercisable or exchangeable for, any capital stock
of the Company or any of its Subsidiaries; (iii) there are no outstanding debt securities, notes,
credit agreements, credit facilities or other agreements, documents or instruments evidencing
Indebtedness of the Company or any of its Subsidiaries or by which the Company or any of its
Subsidiaries is or may become bound; (iv) there are no financing statements securing obligations in
any amounts filed in connection with the Company or any of its Subsidiaries; (v) there are no
agreements or arrangements under which the Company or any of its Subsidiaries is obligated to
register the sale of any of their securities under the 1933 Act (except pursuant to the
Registration Rights Agreement); (vi) there are no outstanding securities or instruments of the
Company or any of its Subsidiaries which contain any redemption or similar provisions, and there
are no contracts, commitments, understandings or arrangements by which the Company or any of its
Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries;
(vii) there are no securities or instruments containing anti-dilution or similar provisions that
will be triggered by the issuance of the Securities; (viii) neither the Company nor any Subsidiary
has any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or
agreement; and (ix) neither the Company nor any of its Subsidiaries have any liabilities or
obligations required to be disclosed in the SEC Documents which are not so disclosed in the SEC
Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries’
respective businesses and which, individually or in the aggregate, do not or could not have a
Material Adverse Effect. The Company has made available to the Buyers true, correct and complete
copies of the Company’s
Certificate of Incorporation, as amended and as in effect on the date hereof (the “Certificate
of Incorporation”), the Company’s bylaws, as amended and as in effect on the date hereof (the
“Bylaws”), and the terms of all securities convertible into, or exercisable or exchangeable for,
shares of Common Stock and the material rights of the holders thereof in respect thereto that have
not been disclosed in the SEC Documents.

 

 

Exhibit A — Form of Series E Warrant

 

 

Exhibit B — Form of Voting Agreementexv10w2

EXHIBIT 10.2

FORM
OF VOTING AGREEMENT

     VOTING AGREEMENT, dated as of January __, 2011 (this “Agreement”), by and among OXiGENE, Inc.,
a Delaware corporation with offices located at 701 Gateway Blvd, Suite 210, South San Francisco, CA
94080 (the “Company”) and [Symphony ViDA Holdings LLC, a Delaware limited liability company with
offices located at 875 Third Avenue, 18th Floor, New York, NY 10022] (the
“Stockholder”).

          WHEREAS, the Company and certain investors (each, an “Investor”, and collectively, the
“Investors”) have entered into a Warrant Exchange Agreement, dated as of the date hereof (the
“Warrant Exchange Agreement”), pursuant to which, among other things, the Company and the Investors
have, severally but not jointly, agreed to exchange the Investors’ Series A Warrants and Series C
Warrants to purchase shares of the Company’s common stock, $0.01 par value per share (the “Common
Stock”), for shares of Common Stock and Series E Warrants, on the terms and subject to the
conditions set forth in the Warrant Exchange Agreement;

          WHEREAS, as of the date hereof, the Stockholder owns shares of Common Stock, which represents
(i) approximately ___% of the total issued and outstanding Common Stock of the Company, and (ii)
approximately ___% of the total voting power of the Company; and

          WHEREAS, as a condition to the willingness of the Investors to enter into the Warrant Exchange
Agreement and to consummate the transactions contemplated thereby (collectively, the
“Transaction”), the Investors have required that the Stockholder agree, and in order to induce the
Investors to enter into the Warrant Exchange Agreement, the Stockholder has agreed, to enter into
this Agreement with respect to all the Common Stock now owned and which may hereafter be acquired
by the Stockholder and any other securities, if any, which Stockholder is currently entitled to
vote, or after the date hereof becomes entitled to vote, at any meeting of the stockholders of the
Company (the “Other Securities”).

          NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements
contained herein, and intending to be legally bound hereby, the parties hereto hereby agree as
follows:

ARTICLE I

VOTING AGREEMENT OF THE STOCKHOLDER

          SECTION 1.01. Voting Agreement. Subject to the last sentence of this Section 1.01,
the Stockholder hereby agrees that at any meeting of the stockholders of the Company, however
called, and in any action by written consent of the Company’s stockholders, the Stockholder shall
vote the Common Stock and the Other Securities: (a) in favor of the Stockholder Approval (as
defined in the Warrant Exchange Agreement), as described in Section 1.2 of the Warrant Exchange
Agreement; and (b) against any proposal or any other corporate action or agreement that would
result in a breach of any covenant, representation or warranty or any other obligation or agreement
of the Company under the Warrant Exchange

 

 

Agreement or which could result in any of the conditions to the Company’s obligations under the Warrant
Exchange Agreement not being fulfilled. The Stockholder acknowledges receipt and review of a copy
of the Warrant Exchange Agreement. The obligations of the Stockholder under this Section 1.01
shall terminate (i) immediately following the occurrence of the Stockholder Approval or (ii) upon
the termination of the Warrant Exchange Agreement pursuant to its terms.

ARTICLE II

REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDER

          The Stockholder hereby represents and warrants to the Company and each of the Investors as
follows:

          SECTION 2.01. Authority Relative to this Agreement. The Stockholder has all
requisite power and authority to execute, deliver and perform its obligations under this Agreement.
This Agreement has been duly executed and delivered by the Stockholder and constitutes a legal,
valid and binding obligation of the Stockholder, enforceable against the Stockholder in accordance
with its terms, except (a) as such enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, fraudulent conveyance, moratorium or similar laws now or hereafter in
effect relating to, or affecting generally, the enforcement of creditors’ and other obligees’
rights and (b) where the remedy of specific performance or other forms of equitable relief may be
subject to certain equitable defenses and principles and to the discretion of the court before
which the proceeding may be brought.

          SECTION 2.02. No Conflict. (a) The execution and delivery of this Agreement by the
Stockholder does not, and the performance of this Agreement by the Stockholder shall not, (i)
conflict with or violate any federal, state or local law, statute, ordinance, rule, regulation,
order, judgment or decree applicable to the Stockholder or by which the Common Stock or the Other
Securities owned by the Stockholder are bound or affected or (ii) result in any breach of or
constitute a default (or an event that with notice or lapse of time or both would become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, or
result in the creation of a lien or encumbrance on any of the Common Stock or the Other Securities
owned by the Stockholder pursuant to, any note, bond, mortgage, indenture, contract, agreement,
lease, license, permit, franchise or other instrument or obligation to which the Stockholder is a
party or by which the Stockholder or the Common Stock or Other Securities owned by the Stockholder
is bound.

          (b) The execution and delivery of this Agreement by the Stockholder does not, and the
performance of this Agreement by the Stockholder shall not, require any consent, approval,
authorization or permit of, or filing with or notification to, any governmental entity by the
Stockholder.

          SECTION 2.03. Title to the Stock. As of the date hereof, the Stockholder is the
owner of ________ shares of Common Stock, entitled to vote, without restriction, on all matters
brought before holders of capital stock of the Company, which Common Stock represents on the date
hereof approximately ____% of the outstanding stock and approximately ____% of the voting power of
the Company. Such Common Stock represents all of the securities of the Company owned, either of
record or beneficially, by the Stockholder. Such Common Stock is owned free and clear of all
security interests, liens, claims, pledges, options, rights of first

-2-

 

refusal, agreements, limitations on the Stockholder’s voting rights, charges and other
encumbrances of any nature whatsoever. The Stockholder has not appointed or granted any proxy,
which appointment or grant is still effective, with respect to the Common Stock or Other Securities
owned by the Stockholder.

ARTICLE III

COVENANTS

          SECTION 3.01. No Disposition or Encumbrance of Stock. The Stockholder hereby
covenants and agrees that, until the termination of this Agreement, the Stockholder shall not
offer or agree to sell, transfer, tender, assign, hypothecate or otherwise dispose of, grant a
proxy or power of attorney with respect to, or create or permit to exist any security interest,
lien, claim, pledge, option, right of first refusal, agreement, limitation on Stockholders’ voting
rights, charge or other encumbrance of any nature whatsoever (“Encumbrance”) with respect to the
Common Stock or Other Securities, directly or indirectly, or initiate, solicit or encourage any
person to take actions which could reasonably be expected to lead to the occurrence of any of the
foregoing.

          SECTION 3.02. Company Cooperation. The Company hereby covenants and agrees that it
will not, and the Stockholder irrevocably and unconditionally acknowledges and agrees that the
Company will not (and waives any rights against the Company in relation thereto), recognize any
Encumbrance on any of the Common Stock or Other Securities subject to this Agreement.

ARTICLE IV

MISCELLANEOUS

          SECTION 4.01. Further Assurances. The Stockholder shall execute and deliver such
further documents and instruments and take all further action as may be reasonably necessary in
order to consummate the transactions contemplated hereby.

          SECTION 4.02. Specific Performance. The parties hereto agree that irreparable damage
would occur in the event any provision of this Agreement was not performed in accordance with the
terms hereof and that any Investor (without being joined by any other Investor) shall be entitled
to specific performance of the terms hereof, in addition to any other remedy at law or in equity.
Any Investor shall be entitled to its reasonable attorneys’ fees in any action brought to enforce
this Agreement in which it is the prevailing party.

          SECTION 4.03. Entire Agreement. This Agreement constitutes the entire agreement
among the Company and the Stockholder (other than the Warrant Exchange Agreement) with respect to
the subject matter hereof and supersedes all prior agreements and understandings, both written and
oral, among the Company and the Stockholder with respect to the subject matter hereof.

          SECTION 4.04. Amendment. This Agreement may not be amended except by an instrument
in writing signed by the parties hereto.

-3-

 

          SECTION 4.05. Severability. If any term or other provision of this Agreement is
invalid, illegal or incapable of being enforced by any rule of law, or public policy, all other
conditions and provisions of this Agreement shall nevertheless remain in full force and effect so
long as the economic or legal substance of this Agreement is not affected in any manner materially
adverse to any party. Upon such determination that any term or other provision is invalid, illegal
or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties as closely as possible in a mutually
acceptable manner in order that the terms of this Agreement remain as originally contemplated to
the fullest extent possible.

          SECTION 4.06. Governing Law. All questions concerning the construction, validity,
enforcement and interpretation of this Agreement shall be governed by the internal laws of the
State of Delaware, without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of Delaware or any other jurisdictions) that would cause the application of
the laws of any jurisdictions other than the State of Delaware. The parties hereby agree that all
actions or proceedings arising directly or indirectly from or in connection with this Agreement
shall be litigated only in the Supreme Court of the State of New York or the United States District
Court for the Southern District of New York located in New York County, New York. The parties
consent to the jurisdiction and venue of the foregoing courts and consent that any process or
notice of motion or other application to any of said courts or a judge thereof may be served inside
or outside the State of New York or the Southern District of New York by registered mail, return
receipt requested, directed to the party being served at its address set forth on the signature
ages to this Agreement (and service so made shall be deemed complete three (3) days after the same
has been posted as aforesaid) or by personal service or in such other manner as may be permissible
under the rules of said courts. Each of the Company and the Stockholder irrevocably waives, to the
fullest extent permitted by law, any objection which it may now or hereafter have to the laying of
the venue of any such suit, action, or proceeding brought in such a court and any claim that suit,
action, or proceeding has been brought in an inconvenient forum. EACH PARTY HEREBY IRREVOCABLY
WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY
DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION
CONTEMPLATED HEREBY.

          SECTION 4.07. Termination. This Agreement shall terminate (i) immediately following
the occurrence of the Stockholder Approval or (ii) upon the termination of the Warrant Exchange
Agreement pursuant to its terms.

[The remainder of the page is intentionally left blank]

-4-

 

IN WITNESS WHEREOF, the Stockholder and the Company has duly executed this Agreement.

	 	 	 	 	 
	 	THE COMPANY:

OXIGENE, INC.

 	 
	 	By:  	 	 
	 	 	Name:  	Peter Langecker 	 
	 	 	Title:  	Chief Executive Officer
	 
	 	 	Address:  	
   OXiGENE, Inc.

701 Gateway Blvd

Suite 210

South San Francisco, CA 94080
 	 
	 	
STOCKHOLDER:

 
	 	 	 

-5-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}]]